SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RESULTS FOR NIMACIMAB IN COMBINATION WITH SEMAGLUTIDE
SKYE BIOSCIENCE INC - 22.3% WEIGHT LOSS AT 52 WEEKS WITH NIMACIMAB + SEMAGLUTIDE (2.4 MG) COMBINATION
SKYE BIOSCIENCE INC - FULL TOPLINE REPORTING OF CBEYOND PHASE 2A DATA EXPECTED Q3 2026
Source text: ID:nGNXc9xN7x
Further company coverage: SKYE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.